124278-39-3

Upstream product

• 1828-66-6 morpholine-4-sulfonyl chloride 
• 63-91-2 L-phenylalanine 

Downstream Products

• 132125-37-2 N-(4-morpholinylsulfonyl)-Phe-His(trit)-ACHPA-AEM 
• 127953-31-5 2-[(S)-2-(Morpholine-4-sulfonylamino)-3-phenyl-propionylamino]-malonic acid benzyl ester methyl ester 
• 137302-31-9 N-(4-morpholinylsulfonyl)-L-phenylalanyl-N-<1(S)-(cyclohexylmethyl)-3,3-difluoro-2(R)-hydroxy-4-<<2-(4-morpholinyl)ethyl>amino>-4-oxobutyl>-4,5-didehydro-L-norvalinamide 
• 137302-50-2 N-<2-<<1(S)-(cyclohexylmethyl)-3,3-difluoro-2(R)-hydroxy-4-<<2-(4-morpholinyl)ethyl>amino>-4-oxobutyl>amino>-2-oxo-1-propoxyethyl>-α-<(4-morpholinylsulfonyl)amino>benzenepropanamide 
• 137429-65-3 N-<2-<<1(S)-(cyclohexylmethyl)-3,3-difluoro-2(R)-hydroxy-4-<<2-(4-morpholinyl)ethyl>amino>-4-oxobutyl>amino>-2-oxo-1-propoxyethyl>-α-<(4-morpholinylsulfonyl)amino>benzenepropanamide 
• 137429-60-8 (4-{(S)-[(1S,2R)-1-Cyclohexylmethyl-3,3-difluoro-2-hydroxy-3-(2-morpholin-4-yl-ethylcarbamoyl)-propylcarbamoyl]-[(S)-2-(morpholine-4-sulfonylamino)-3-phenyl-propionylamino]-methyl}-thiazol-2-yl)-carbamic acid benzyl ester 
• 137302-86-4 (4-{(S)-2-[(1S,2R)-1-Cyclohexylmethyl-3,3-difluoro-2-hydroxy-3-(2-morpholin-4-yl-ethylcarbamoyl)-propylcarbamoyl]-2-[(S)-2-(morpholine-4-sulfonylamino)-3-phenyl-propionylamino]-ethyl}-thiazol-2-yl)-carbamic acid trichloromethyl ester 
• 137302-84-2 (3R,4S)-5-Cyclohexyl-2,2-difluoro-3-hydroxy-4-[(S)-2-[(S)-2-(morpholine-4-sulfonylamino)-3-phenyl-propionylamino]-3-(1-trityl-1H-imidazol-4-yl)-propionylamino]-pentanoic acid (2-morpholin-4-yl-ethyl)-amide 
• 142131-04-2 (S)-2-[(S)-2-(Morpholine-4-sulfonylamino)-3-phenyl-propionylamino]-3-thiazol-4-yl-propionic acid benzyl ester 
• 135704-07-3 (4-{(S)-2-{(S)-1-[(S)-1-Hydroxy-2-((S)-2-methyl-butylcarbamoyl)-ethyl]-3-methyl-butylcarbamoyl}-2-[(S)-2-(morpholine-4-sulfonylamino)-3-phenyl-propionylamino]-ethyl}-thiazol-2-yl)-carbamic acid benzyl ester 
• 135704-19-7 (3R,4S)-5-Cyclohexyl-2,2-difluoro-3-hydroxy-4-{(S)-2-[(S)-2-(morpholine-4-sulfonylamino)-3-phenyl-propionylamino]-3-[2-(2,2,2-trichloro-ethoxycarbonylamino)-thiazol-4-yl]-propionylamino}-pentanoic acid ethyl ester 
• 135704-04-0 (4-{(S)-2-[(1S,2S)-1-Cyclohexylmethyl-2-hydroxy-3-(2-morpholin-4-yl-ethylcarbamoyl)-propylcarbamoyl]-2-[(S)-2-(morpholine-4-sulfonylamino)-3-phenyl-propionylamino]-ethyl}-thiazol-2-yl)-carbamic acid benzyl ester 
• 135704-18-6 (4-{(S)-2-((1S,2S)-3-{2-[Bis-(2-hydroxy-ethyl)-amino]-ethylcarbamoyl}-1-cyclohexylmethyl-2-hydroxy-propylcarbamoyl)-2-[(S)-2-(morpholine-4-sulfonylamino)-3-phenyl-propionylamino]-ethyl}-thiazol-2-yl)-carbamic acid benzyl ester 
• 142211-46-9 (4-{(S)-2-((1S,2S,4R)-1-Cyclohexylmethyl-2,4-dihydroxy-hexylcarbamoyl)-2-[(S)-2-(morpholine-4-sulfonylamino)-3-phenyl-propionylamino]-ethyl}-thiazol-2-yl)-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Renin inhibitors containing α-heteroatom amino acids as P2 residues

A series of renin inhibitors having α-heteroatom amino acids as P2 substitutions has been prepared. Examples where the heteroatom is oxygen, sulfur, or nitrogen are described. Many of the compounds exhibit subnanomolar potency when tested in vi

Renin Inhibitors Containing Esters at the P2-Position. Oral Activity in a Derivative of Methyl Aminomalonate

A series of renin inhibitors containing ester side chains at the P2 subsite are potent inhibitors of primate renin.Derivatives containing the diol isostere (ACDMH) at P1-P'1 were the most potent inhibitors.Moderate selectivity for re